FDA accepts supplemental BLA for Genentech’s Polivy combination for previously untreated diffuse large B-cell lymphoma

Columvi improves OS in R/R DLBCL in phase III trial

Genentech’s phase III STARGLO study met its primary endpoint of overall survival.

April 19, 2024

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.

April 05, 2024

Vol.50 No.14

Drugs & Targets

FDA grants accelerated approval to Brukinsa for R/R follicular lymphoma

FDA granted accelerated approval to Brukinsa (zanubrutinib) with obinutuzumab for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

March 08, 2024

Vol.50 No.10

Drugs & Targets

FDA grants Epkinly priority review sBLA for difficult-to-treat R/R follicular lymphoma

FDA has granted Breakthrough Therapy Designation to Epkinly (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

March 01, 2024

Vol.50 No.09

Clinical Roundup

Inavolisib combination demonstrates 57% PFS in breast cancer indication

The phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer, demonstrated positive results.

January 05, 2024

Vol.50 No.01

Clinical Roundup

Kadcyla demonstrates OS benefit in breast cancer indication

The phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment demonstrated positive long-term follow-up data.

January 05, 2024

Vol.50 No.01

FDA accepts supplemental BLA for Genentech’s Polivy combination for previously untreated diffuse large B-cell lymphoma

YOU MAY BE INTERESTED IN

Columvi improves OS in R/R DLBCL in phase III trial

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

FDA grants accelerated approval to Brukinsa for R/R follicular lymphoma

FDA grants Epkinly priority review sBLA for difficult-to-treat R/R follicular lymphoma

Inavolisib combination demonstrates 57% PFS in breast cancer indication

Kadcyla demonstrates OS benefit in breast cancer indication

Renew today!

Subscriber content

Login